As the clinical focus shifts toward the growing complexities of chronic weight management, the demand for high-quality, reliable data in obesity trials has never been greater. DelRicht Research has proven to be a cornerstone partner for sponsors navigating the complexities of chronic weight management and its associated comorbidities. By combining aggressive, targeted recruitment strategies with a streamlined operational model designed to maximize patient retention, DelRicht continues to set a high standard for clinical excellence in the obesity research space.

Strategic Site Footprint and Investigator Expertise

DelRicht Research deployed a powerhouse network of four high-performing sites for this protocol, spanning key markets to ensure patient diversity and rapid enrollment. Our success is anchored by a roster of experienced Principal Investigators who specialize in the complexities of obesity and weight management trials:

– Dr. Melita Tate | Tulsa, OK
– Dr. Olabisi Badmus | Charlotte, NC
– Dr. Robert Springer | Atlanta, GA
– Dr. Sean Kerby | Gulfport, MS

Operational Efficiency: Redefining Startup Timelines

DelRicht Research prides itself on a “rapid-start” infrastructure that minimizes the gap between award and activation. Our network demonstrated industry-leading agility with an average activation to screen time of just 1 day across 4 participating sites. Our Atlanta and Charlotte sites achieved a remarkable first patient first visit the same day as activation.

Our centralized regulatory team ensures that essential documents are turned around within 24 hours and CTA/Budget reviews are completed within 48 hours, resulting in rapid receipt-to-execution timelines.

Overcoming Key Challenges

Large-scale obesity trials present unique hurdles that can threaten both the timeline and the quality of the metabolic data collected. The two key challenges that sites conducting the study faced were participant retention due through visit fatigue and protocol adherence through fasting compliance.

Double-blind obesity trials often see high attrition due to the motivational impact of placebo-driven results. When paired with a schedule of weekly in-clinic visits for subcutaneous injections administered by site staff, the risk of visit fatigue and subsequent discontinuation is substantial. DelRicht leveraged participant-centric approach through education and engagement strategies: proactive placebo expectation management, travel stipends, and optimized scheduling through consistent weekly schedules tailored to participant preferences.

The rigorous requirement for fasting lab draws introduces significant participant burden. Failure to maintain a fasting state results in protocol deviations and incomplete metabolic data sets, which directly impacts the robustness of the primary endpoint analysis. To directly address this challenge, we implemented a pre-visist notification protocol to ensure fasting and medication compliance. This reduced participant burden and maximized evaluable data points by minimizing reschedule and protocol deviations.

What This Means for Sponsors and CROs

This study reinforces the competitive advantages of partnering with a fully aligned site network for complex metabolic research:

– Rapid Screening: Near-instant screening ensures your study hits the ground running.
– Reliable Data: By solving for fasting compliance and diary adherence at the site level, we deliver cleaner data sets for primary endpoint analysis.
– Elite Enrollment Power: Our ability to over-enroll by nearly 60% provides sponsors with the buffer needed to stay ahead of global timelines.

Partner With DelRicht Research

From rapid startup to high-retention patient management, DelRicht Research delivers the infrastructure and expertise required for modern phase 3 obesity and weight management trials. If you are planning an upcoming metabolic or obesity study, our team is ready to accelerate your timelines and exceed your enrollment targets.

Learn more at www.DelRichtResearch.com or connect with us to discuss your next clinical program.